Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Slovenia

Marie Skłodowska-Curie Action · Running

LLIMIT Lectin ligands for modulation of immunity

Coordinator
Univerza V Ljubljani, Slovenia
Runs
1 October 2026 to 30 September 2030
Status
Running
EU funding
€4.3m
Total cost
—
Partners
13 organisations in 8 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101311719

What the project is doing

In the project's own words, from its summary on CORDIS.

LLIMIT (Lectin LIgands for Modulation of ImmuniTy) is a European doctoral training network dedicated to advancing immunomodulatory glycoscience. The network aims to equip a new generation of researchers with the skills to design and develop ligands that target immune-related lectins - an innovative, yet under-explored therapeutic strategy against immune disorders, which are among today’s major global health challenges.

The consortium unites seven academic institutions with accredited PhD programmes in organic and medicinal chemistry, structural biology, immunology and pharmacology, each with strong expertise in glycoscience. They are joined by six non-academic partners and a graduate and research academy, ensuring comprehensive, cross-sector training that spans fundamental science, translational research, and entrepreneurship. Key objectives of LLIMIT include:•Recruiting and training 14 doctoral candidates in a joint research-based programme supported by expert supervision and specialised training events.•Advancing innovative research on immune lectins and carbohydrate ligands, covering the full early drug discovery pipeline, from target identification and validation to advanced glycochemistry, drug design, and hit and lead discovery.•Establishing a sustainable foundation for European excellence in glycodrug and immunomodulatory research.•Developing a common glycodrug curriculum across participating institutions to standardise and strengthen education in this field.•Building and maintaining long-term partnerships that ensure continuity in training, research, and innovation well beyond the project’s duration.

By achieving these goals, LLIMIT will bridge the gap between Europe’s outstanding glycoscience research and the urgent need for novel glycodrugs.

Topics

Who is involved

OrganisationCityCountryRole
Univerza V LjubljaniLjubljanaSloveniaCoordinator
Universitat BaselBaselSwitzerlandParticipant
Bimovis GmbHHeidelbergGermanyAssociatedpartner
Crelux GmbHMartinsriedGermanyAssociatedpartner
Heinrich-Heine-Universitaet DuesseldorfDusseldorfGermanyParticipant
GlycodiagChevillyFranceAssociatedpartner
Universite Grenoble AlpesGrenobleFranceParticipant
Selvita DooZagrebCroatiaAssociatedpartner
Universita Degli Studi Di MilanoMilanoItalyParticipant
Universiteit UtrechtUtrechtNetherlandsParticipant
Lunds UniversitetLundSwedenParticipant
Rg Discovery ABLundSwedenAssociatedpartner
Saromics Biostructures ABLundSwedenAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI